clinical trial · NCT07124936
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·phase2·recruiting·n = 97
Diffuse Large B Cell Lymphoma (DLBCL)HDM2005Rituximab or Rituximab biosimilarGemcitabineOxaliplatinCyclophosphamideDoxorubicinPrednisone
brief summary
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.
started
Jul 30, 2025
primary completion
Oct 26, 2027
completion
Oct 25, 2029
last updated
Aug 15, 2025
official title
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol